MedTrace Logo

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

NCT02549196 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-03-05

Study results available
· View outcomes & findings →

Summary

This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.

Conditions

  • Dementia of Alzheimer's Type

Interventions

DRUG

Donepezil

Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

DRUG

Solifenacin

Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

Sponsors & Collaborators

  • Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Lynn James · Allergan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-07
Primary Completion
2017-09-28
Completion
2017-09-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549196 on ClinicalTrials.gov